Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2013 Results
Date:5/9/2013

57,250(1)  Unaudited(2)  Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses OPERATIONAL HIGHLIGHTSOn March 25, 2013, Vanda announced that it held a pre-NDA meeting with the Division of Neurology Products of the FDA to discuss the regulatory path for filing an NDA for tasimelteon, a circadian regulator, for the treatment of Non-24.  At the pre-NDA meeting, the FDA confirmed that the efficacy and safety data proposed by Vanda to be submitted in the tasimelteon NDA for Non-24 is adequate to support filing.  The NDA supporting package that includes data from clinical pharmacology, pre-clinical pharmacology program, chemistry and manufacturing was also deemed adequate to support filing. Based on this successful completion of the pre-NDA meeting, Vanda is targeting an NDA submission for tasimelteon in mid-2013.  Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals.  Currently there is no FDA approved treatment for Non-24. 

Vanda continues to expand its activities in support of Non-24 disease awareness and education with professional, advocacy and patient groups.  In June 2013, Vanda will present data from the SET and RESET studies at the 27th Annual Meeting of the Associated Professional Sleep Societies, SLEEP 2013, and the 95th Annual Endocrine Society Meeting, ENDO 2013.  In addition, Vanda continues to build its registry of individuals who have the potential to be Non-24 patients.
The U.S. based registry has over 1,500 individuals and was created to facilitate the recruitment of patients for the tasimelteon Non-24 clinical studies. 

On April 25, 2013, Vanda and Bristol-Myers Squibb (BMS) entered into an amendment to the tasimelteon licensing agreement.  Subsequent to this amendment, BMS waived its option to re-acquire rights to develop and commercialize tasimelteon in count
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
3. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
4. Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
5. Adamis Pharmaceuticals CEO Provides Update for Shareholders
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
8. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
9. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
10. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
11. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 Seventh Wave Laboratories, a consulting-based ... of pharmaceutical products and medical devices, announced the purchase ... a 50,000 sq. ft. building more than three times ... growth. Facility renovations will begin immediately and the gradual ... occur in September. , “We are excited about ...
(Date:5/21/2015)... May 21, 2015  Prima Biomed Ltd. (NASDAQ: ... striving to become a leader in the development of ... that the final CVac data from the Phase II ... trend for a clinically meaningful improvement in Overall Survival ... patients. In the group of second remission ...
(Date:5/21/2015)... -- Imagine being able to probe and ... others. Being able to read faces and enjoy genuine ... anticipate their thoughts and actions like never before. Use ... create unique abstract paintings and video, or, play a ... first-person-shooter as it creates action, dialog, and outcomes based ...
(Date:5/21/2015)... 2015  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced positive updated results from its ... the treatment of unresectable glioblastoma multiforme (GBM), a ... trial is designed to investigate the preliminary efficacy ... have progressed following prior treatment with surgery, radiation ...
Breaking Biology Technology:Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... OmniComm Systems, Inc. (OTC Bulletin Board: OMCM) announced that ... LLC for the purpose of resolving the patent infringement ... entered into a licensing arrangement with DataSci. OmniComm ... have come to an agreement in this matter. ...
... (NasdaqGS: VARI) plans to release its financial results for the ... Pacific Time (PT) on Wednesday, April 29, 2009. A live ... review those quarterly results is scheduled to follow at 2:00 ... from Varian, Inc.,s Web site at www.varianinc.com ...
... BUDAPEST, Hungary, April 15 ChemAxon, a software,solutions ... version,5.2 of their cheminformatics toolkits, Marvin & JChem. ... options and improvements in search,performance. , ... suite of application programming interfaces,(API,s) and graphic user ...
Cached Biology Technology:OmniComm Systems Announces Settlement of Patent Litigation With DataSci, LLC 2ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks 2
(Date:4/27/2015)... more than four decades, AUVSI,s Unmanned Systems ... event for the unmanned land, sea, and air industries. ... local, national, or trade news organization interested in gathering ... applications of unmanned technologies. The conference will explore the ... and how it will soon impact the lives of ...
(Date:4/21/2015)... April 21, 2015 High ... policies are boosting access control systems market in ... to a recently published report by TechSci Research " ... the access control systems market in Saudi ... by 2020.The access control systems market in the Kingdom ...
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... use increasingly threatening signals to ward off trespassing rivals. First ... waving a bird,s version of "flipping the bird" ... signals have failed, attack. This hierarchical warning scheme, ... to a communication system that has been long-used as a ...
... SHREWSBURY, MA -- A study published today in ... presented compelling data showing the consumption of both high fructose ... with average daily consumption do not increase liver fat in ... The findings also add to an already well-established body of ...
... and trainers as career killers, Achilles tendon injuries are among ... nuclear fallout in post WWII tests, scientists have learned why: ... Achilles tendon is a tissue that does not repair itself. ... Journal . "Tendon injury is a very common ...
Cached Biology News:'Get off my lawn:' Song sparrows escalate territorial threats - with video 2'Get off my lawn:' Song sparrows escalate territorial threats - with video 3New study finds neither HFCS nor table sugar increases liver fat under 'real world' conditions 2Fallout from nuclear testing shows that the Achilles tendon can't heal itself 2
... LC Sciences provides a comprehensive epitope ... microarrays synthesized on Paraflo microfluidic chips ... biosensor development. This comprehensive service includes ... assays using sample(s) provided by you, ...
... ,Schistosomal glutathione-S-transferase (GST) is commonly ... proteins in E. coli (1). The GSTTag ... production and in some cases the solubility ... a soluble, properly folded form, GSTTag fusion ...
... used as a fusion partner when expressing ... sequence has been reported to enhance the ... of its fusion partners. When expressed in ... proteins can be purified with immobilized glutathione. ...
... Cell Kit with Medium High quality ready-to-use ... optimized base medium for growth and lineage ... cells generated from E18 fetal rat brain ... tissue-like mixture of in vitro stem/progenitor cells, ...
Biology Products: